Bertagna Francesco, Motta Federica, Bertoli Mattia, Bosio Giovanni, Fisogni Simona, Tardanico Regina, Ferrari Vittorio, Antonelli Alessandro, Simeone Claudio, Cosciani Cunico Sergio, Giubbini Raffaele
Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy.
Nucl Med Rev Cent East Eur. 2013;16(1):3-8. doi: 10.5603/NMR.2013.0002.
Renalcancers account for around 3% of all cancers and the most common type of (90%) is renal cell carcinoma Five-year survival rate in renal cancer patients is 68.4%.
The aim of our study was to establish the role of F18-FDG-PET/CT in restaging patients with renal carcinoma who underwent partial or radical nephrectomy. Secondary aim of the study was to identify histological characteristics of the primary tumour that may be responsible for the metabolic behaviour of neoplastic lesions.
We retrospectively evaluated 68 patients with renal carcinoma in whom F18-FDG-PET/CT was performed.
Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of F18-FDG PET/CT were 82%, 100%, 100%, 66.7% and 86.8%, respectively.
The results of our study suggest that F18-FDG PET/CT is characterised by high specificity and positive predictive value and can be useful in restaging patients affected by renal carcinoma. However, due to low negative predictive value, this method cannot be recommended for definitely ruling out suspected disease relapse.
肾癌约占所有癌症的3%，最常见的类型（90%）是肾细胞癌。肾癌患者的五年生存率为68.4%。
我们研究的目的是确定F18-FDG-PET/CT在对接受部分或根治性肾切除术的肾癌患者进行再分期中的作用。该研究的次要目的是确定可能导致肿瘤病变代谢行为的原发性肿瘤的组织学特征。
我们回顾性评估了68例接受F18-FDG-PET/CT检查的肾癌患者。
F18-FDG PET/CT的敏感性、特异性、阳性预测值、阴性预测值和准确性分别为82%、100%、100%、66.7%和86.8%。
我们的研究结果表明，F18-FDG PET/CT具有高特异性和阳性预测值，可用于对肾癌患者进行再分期。然而，由于阴性预测值较低，不推荐使用该方法明确排除疑似疾病复发。
